IPP Bureau
Briefs: Torrent Pharmaceuticals and Hemant Surgical Industries
By IPP Bureau - September 12, 2025
Hemant Surgical Industries receives order
Dr. Reddy’s acquires J&J’s Stugeron portfolio to foray into anti-vertigo segment
By IPP Bureau - September 11, 2025
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery
By IPP Bureau - September 11, 2025
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Novo Nordisk to cut 9,000 jobs globally
By IPP Bureau - September 11, 2025
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Mankind Pharma gets CDSCO nod to begin Phase 1 trials of novel Autoimmune drug candidate MKP11093
By IPP Bureau - September 10, 2025
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Sirio secures TGA GMP certification to support strategic growth in Australia
By IPP Bureau - September 10, 2025
The Ma’anshan site approval covers pastilles, oral liquids, and powders
FDA prohibits Sun Pharma's Halol Plant from exporting drugs to US
By IPP Bureau - September 10, 2025
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
Cupid to acquire strategic stake in Mansam fragrance brand, Saudi Arabia
By IPP Bureau - September 10, 2025
Mansam, founded in 2022, is positioned as the first Arabian luxury fragrance brand with a vision for global expansion
Dabur's NewU signs Unicommerce to power its omnichannel operations
By IPP Bureau - September 10, 2025
Schneider Electric and Apollo Hospitals collaborate for energy-efficient healthcare solutions
By IPP Bureau - September 10, 2025
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Botanic Healthcare launches Rs. 25 crore liposomal manufacturing facility in Hyderabad
By IPP Bureau - September 10, 2025
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Evonik and Ethris partner to expand offerings for nucleic acid delivery
By IPP Bureau - September 10, 2025
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Navin Fluorine inaugurates Phase-1 of new cGMP-4 facility of Navin Molecular at Devas
By IPP Bureau - September 10, 2025
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Novartis to acquire Tourmaline Bio for $1.4 billion
By IPP Bureau - September 10, 2025
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
